ICU Medical, Inc. $ICUI Shares Bought by Kirr Marbach & Co. LLC IN

Kirr Marbach & Co. LLC IN grew its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 18.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,153 shares of the medical instruments supplier’s stock after acquiring an additional 6,863 shares during the period. Kirr Marbach & Co. LLC IN owned about 0.18% of ICU Medical worth $5,702,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Millennium Management LLC raised its position in ICU Medical by 173.4% in the third quarter. Millennium Management LLC now owns 1,089,017 shares of the medical instruments supplier’s stock valued at $130,638,000 after purchasing an additional 690,694 shares during the period. Norges Bank purchased a new stake in shares of ICU Medical during the 4th quarter valued at about $58,083,000. Thrivent Financial for Lutherans lifted its position in ICU Medical by 1,604.0% during the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock worth $43,294,000 after acquiring an additional 285,648 shares in the last quarter. UBS Group AG lifted its position in ICU Medical by 239.8% during the 3rd quarter. UBS Group AG now owns 386,555 shares of the medical instruments supplier’s stock worth $46,371,000 after acquiring an additional 272,782 shares in the last quarter. Finally, Brown Advisory Inc. purchased a new position in ICU Medical in the 4th quarter worth approximately $32,445,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Insider Activity

In related news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. This trade represents a 23.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

ICUI has been the topic of a number of analyst reports. KeyCorp dropped their price objective on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research note on Monday, April 27th. Weiss Ratings upgraded shares of ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. BTIG Research assumed coverage on shares of ICU Medical in a report on Monday, June 15th. They issued a “buy” rating and a $170.00 price objective on the stock. Finally, Piper Sandler decreased their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $168.40.

ICU Medical Stock Performance

ICU Medical stock opened at $135.82 on Wednesday. ICU Medical, Inc. has a 52 week low of $107.00 and a 52 week high of $160.29. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. The stock has a market cap of $3.39 billion, a P/E ratio of 73.42, a price-to-earnings-growth ratio of 1.90 and a beta of 0.77. The stock has a 50 day moving average of $130.36 and a 200-day moving average of $138.31.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business’s revenue was down 12.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, analysts expect that ICU Medical, Inc. will post 6.5 EPS for the current fiscal year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.